Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xun Lin

Showing results (191-200 of 210) with videos related to

Pageof 21
Sort By:
European Urology|October 3, 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsRobert J Motzer, Alain Ravaud, Jean-Jacques Patard, et al.
Future Oncology (London, England)|June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genesKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Frontiers in Immunology|January 23, 2023
Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer's diseaseJian Chen, An-Xiang Dai, Hai-Liang Tang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
The New England Journal of Medicine|October 11, 2016
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Pageof 21

Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
European Urology|October 3, 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsRobert J Motzer, Alain Ravaud, Jean-Jacques Patard, et al.
Future Oncology (London, England)|June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genesKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Frontiers in Immunology|January 23, 2023
Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer's diseaseJian Chen, An-Xiang Dai, Hai-Liang Tang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
The New England Journal of Medicine|October 11, 2016
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Pageof 21